Israeli lipids ingredients specialist Enzymotec has acquired an American supplement developer in a move to revitalize its stumbling medical foods subsidiary that has run into regulatory difficulties in the United States.
Combining the probiotic Lactobacillus reuteri with the protein tryptophan could help promote greater ‘tolerance’ in immune cells in the gut, according to new animal data.
Omega-3 deficiency and heightened inflammation are associated with prenatal depression (PND), with the former resulting in longer depressive episodes, according to a recent Taiwanese study.
A signalling molecule produced by the the omega-3 fatty acid DHA could be used to target age-related conditions and diseases including stroke and Alzheimer’s, new research suggests.
The European Commission (EC) has conditionally cleared a two-way deal acquisition between FMC and DuPont, based on promises that both companies will divest parts of their existing business.
People with heart failure have been found to have less gut bacteria diversity and lack certain important species groups. So are changes in our microbiome causing heart disease, or visa-versa?
The probiotics sector is forecast to soar by 23% in China to 2020 and even greater long-term growth beckons if the industry unites to better educate consumers and regulators.
There is considerable promise in manipulating the gut microbiome to treat the two main forms of inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease, according to a new review.
Microbiome app developer DayTwo has secured €12 million (€10.6m) investment from Seventure Partners’ Health for Life Capital fund, as part of a series A round of fundraising.
A higher ratio of omega-3 to omega-6 enzymes is linked to better survival rate in bowel cancer according to a recent study published in the British Journal of Cancer.
Lonza expects to complete its $5.5bn (€5.2bn) takeover of Capsugel SA in the next few days having secured approval from competition authorities around the world.
Four-week supplementation with vitamin K2 MK-7 (menaquinone-7) significantly improves vascular calcification (VC), according to a new study published in BMC Nephrology.
